Diaceutics PLC

Diaceutics PLC is a United Kingdom-based biotechnology and pharmaceutical company that was founded in 2005. The company's slogan, "Better Testing, Better Treatment," reflects its core mission of ensuring that every patient receives the right treatment at the right time. Diaceutics offers an end-to-end solution to pharmaceutical companies for launching precision medicine diagnostics through its innovative DXRX platform, known as The Diagnostic Network®. This platform, DXRX, is a pioneering diagnostic commercialization platform for precision medicine, uniquely integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. The company has garnered significant attention from investors, with its last investment being a substantial £4.00MPost-IPO Debt investment, which took place on 26 August 2020. Notably, this investment was secured from Silicon Valley Bank. In summary, Diaceutics PLC has positioned itself at the forefront of precision medicine, providing valuable support to pharmaceutical companies. With its innovative platform and strong investor backing, the company is well-positioned to continue driving advancements in the field of diagnostic testing and precision medicine.